Skip to main content

FDA advisors reject Biogen's ALS drug for rare and aggressive form of the disease

FDA advisors voted against Biogen's investigational ALS drug, which could become the first to target a genetic cause of the disease.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.